LUCID DIAGNOSTICS INC.

LUCD11 Dec 2024
Healthcare
$0.82
+0.03 (+2.83%)
Lowest Today
$0.8
Highest Today
$0.83
Today’s Open
$0.82
Prev. Close
$0.79
52 Week High
$1.58
52 Week Low
$0.63
To Invest in LUCID DIAGNOSTICS INC.

LUCID DIAGNOSTICS INC.

Healthcare
LUCD11 Dec 2024
+0.03 (+2.83%)
1M
3M
6M
1Y
5Y
Low
$0.8
Day’s Range
High
$0.83
0.8
52 Week Low
$0.63
52-Week Range
52 Week High
$1.58
0.63
1 Day
-
1 Week
-12.04%
1 month return
-25.26%
3 month return
-5.9%
6 month return
+8.44%
1 Year return
-45%
3 Years return
-87.02%
5 Years return
-
10 Years return
-
Institutional Holdings
Luminus Management, LLC
1.94
Vanguard Group Inc
0.95
Vanguard Total Stock Mkt Idx Inv
0.62
Geode Capital Management, LLC
0.36
Vanguard Institutional Extnd Mkt Idx Tr
0.33
Nantahala Capital Management, LLC
0.21
Fidelity Extended Market Index
0.17

Market Status

Fundamentals
Market Cap
48.3 mln
PB Ratio
2.16
PE Ratio
0
Enterprise Value
104.35 mln
Total Assets
27.27 mln
Volume

Company Financials

Fund house & investment objective

Company Information
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. operates as a subsidiary of PAVmed Inc.
Organisation
LUCID DIAGNOSTICS INC.
Employees
70
Industry
Medical Devices
CEO
Dr. Lishan  Aklog M.D.
Trading and brokerage services provided by
Technology Services provided by Motilal Oswal Financial Services:

Take your next step

Click here to see your activities